- Anrikefon significantly reduced itch severity in CKD patients.
- 37% of anrikefon patients had a 4-point itch score reduction by week 12.
- Quality of life scores improved in the anrikefon group.
- Dizziness was the most common adverse effect.
- The trial enrolled 652 participants across 50 centers in China.
- Anrikefon's efficacy is comparable to difelikefalin with a lower dose.
- Results suggest potential as a new treatment for CKD-associated pruritus.
Source: The BMJ
